These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2893209)

  • 1. Intranasal calcitonin and prevention of postmenopausal bone loss.
    Thamsborg G; Storm T; Sykulski R; Brinch E; Andersen NF; Holmegard SN; Soerensen OH
    Lancet; 1988 Feb; 1(8582):413. PubMed ID: 2893209
    [No Abstract]   [Full Text] [Related]  

  • 2. 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin.
    Reginster JY; Denis D; Albert A; Deroisy R; Lecart MP; Fontaine MA; Lambelin P; Franchimont P
    Lancet; 1987 Dec; 2(8574):1481-3. PubMed ID: 2892047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.
    Plosker GL; McTavish D
    Drugs Aging; 1996 May; 8(5):378-400. PubMed ID: 8935399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectiveness of intranasal salmon calcitonin treatment in postmenopausal osteoporosis].
    Kopaliani M
    Georgian Med News; 2005 Apr; (121):38-42. PubMed ID: 15908722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study.
    Luengo M; Pons F; Martinez de Osaba MJ; Picado C
    Thorax; 1994 Nov; 49(11):1099-102. PubMed ID: 7831624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone loss in young women with primary hypogonadism and its prevention with calcitonin.
    Biberoğlu K; Yildiz A; Kandemir O
    Gynecol Obstet Invest; 1993; 36(2):114-8. PubMed ID: 8225045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Calcitonin in the prevention and therapy of osteoporosis].
    Ringe JD
    Ther Umsch; 1991 Feb; 48(2):91-9. PubMed ID: 2035172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitonin intranasal--unigene: Salcatonin intranasal--unigene.
    Drugs R D; 2004; 5(2):90-3. PubMed ID: 15293868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal calcitonin for prevention and treatment of osteoporosis.
    Christiansen C
    Ann Chir Gynaecol; 1988; 77(5-6):229-34. PubMed ID: 3076050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
    Reginster JY; Denis D; Deroisy R; Lecart MP; De Longueville M; Zegels B; Sarlet N; Noirfalisse P; Franchimont P
    J Bone Miner Res; 1994 Jan; 9(1):69-73. PubMed ID: 8154311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcitonins and osteoporosis.
    Gennari C; Agnusdei D
    Br J Clin Pract; 1994; 48(4):196-200. PubMed ID: 7917799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salmon calcitonin: state of the art in prevention of postmenopausal bone loss?
    Reginster JY; Deroisy R; Denis D; Lecart MP; Franchimont P
    Acta Belg Med Phys; 1989; 12(2):41-6. PubMed ID: 2690544
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.
    Sambrook P; Birmingham J; Kelly P; Kempler S; Nguyen T; Pocock N; Eisman J
    N Engl J Med; 1993 Jun; 328(24):1747-52. PubMed ID: 7684512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study.
    Pontiroli AE; Pajetta E; Calderara A; Alberetto M; Pozza G; Manganelli V; Resmini G; Tessari L; Maresca V
    J Endocrinol Invest; 1991 Jan; 14(1):47-51. PubMed ID: 1646250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
    Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
    J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis.
    Siminoski K; Josse RG
    CMAJ; 1996 Oct; 155(7):962-5. PubMed ID: 8837547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Non-hormonal treatment of postmenopausal osteoporosis].
    Briançon D; Meunier PJ
    Rev Fr Gynecol Obstet; 1987 Dec; 82(12):713-8. PubMed ID: 3324271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis.
    Tekeoğlu I; Adak B; Budancamanak M; Demirel A; Ediz L
    Rheumatol Int; 2005 Dec; 26(2):157-61. PubMed ID: 15660234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women.
    Overgaard K; Agnusdei D; Hansen MA; Maioli E; Christiansen C; Gennari C
    J Clin Endocrinol Metab; 1991 Feb; 72(2):344-9. PubMed ID: 1846873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.